Icosavax lands $100M to take its virus-like particle vaccines into clinical trials

  • by

Icosavax Covid-19 vaccine

RA Capital led the $100 million Series B round of funding for Icosavax, a startup developing vaccines based on virus-like particles. The biotech is preparing for clinical tests of vaccines for respiratory syncytial virus, human metapneumovirus, and SARS-CoV-2.